CN117143242A - Monoclonal antibody composition for resisting Galectin-3 protein and application thereof - Google Patents

Monoclonal antibody composition for resisting Galectin-3 protein and application thereof Download PDF

Info

Publication number
CN117143242A
CN117143242A CN202311420944.XA CN202311420944A CN117143242A CN 117143242 A CN117143242 A CN 117143242A CN 202311420944 A CN202311420944 A CN 202311420944A CN 117143242 A CN117143242 A CN 117143242A
Authority
CN
China
Prior art keywords
galectin
amino acid
acid sequence
protein
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202311420944.XA
Other languages
Chinese (zh)
Other versions
CN117143242B (en
Inventor
芮兵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Baikang Biotechnology Co ltd
Original Assignee
Nanjing Baikang Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Baikang Biotechnology Co ltd filed Critical Nanjing Baikang Biotechnology Co ltd
Priority to CN202311420944.XA priority Critical patent/CN117143242B/en
Publication of CN117143242A publication Critical patent/CN117143242A/en
Application granted granted Critical
Publication of CN117143242B publication Critical patent/CN117143242B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/76—Chemiluminescence; Bioluminescence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention discloses a monoclonal antibody composition for resisting Galectin-3 protein and application thereof, wherein the monoclonal antibody composition comprises Galectin-3-Clone1 and Galectin-3-Clone2, the amino acid sequence of a heavy chain variable region of Galectin-3-Clone1 is shown as SEQ ID NO.1, and the amino acid sequence of a light chain variable region of Galectin-3-Clone1 is shown as SEQ ID NO. 2; the amino acid sequence of the heavy chain variable region of Galectin-3-Clone2 is shown as SEQ ID NO.3, and the amino acid sequence of the light chain variable region of Galectin-3-Clone2 is shown as SEQ ID NO. 4. The preparation method comprises the following steps: and (3) carrying out equal volume mixing emulsification on the Galectin-3 after affinity purification and Freund's adjuvant, collecting blood of mice, separating serum, screening mice with better immunity, carrying out hybridoma fusion experiments, taking the Galectin-3 as an ELISA plate coating antigen, taking supernatant, carrying out ELISA, screening out high-quality positive cell strains, and carrying out two rounds of cell subcloning. Meanwhile, the chemiluminescent diagnostic detection kit of the antibody is also provided, so that the specificity and sensitivity of the diagnostic reagent are improved.

Description

Monoclonal antibody composition for resisting Galectin-3 protein and application thereof
Technical Field
The invention belongs to the field of antibody preparation and sequence determination, and particularly relates to an anti-Galectin-3 protein monoclonal antibody composition and application.
Background
Galectin-3 (Galectin-3, gal-3) is a soluble β -galactoside binding protein, gal-3 belongs to the family of β -galactoside binding lectins, and is characterized by the LGALS3 gene coding on chromosome lpl, consisting of 251 amino acid residues, having a relative molecular mass of 29-35 Kd, and having a Carbohydrate Recognition Domain (CRD) and an amino terminal polypeptide tail region. Gal-3 can exert various physiological functions such as cell growth, differentiation, cell adhesion, tissue repair, etc. It is expressed in a variety of tissues and different types of cells, including macrophages, eosinophils, neutrophils and mast cells. Depending on the location of the distribution, there are also relative differences in functions such as splicing, cell proliferation, differentiation and apoptosis of intracellular Gal-3 major pre-mRNA, while extracellular Gal-3 has the ability to modulate late glycosylation end product receptor function, tumor metastasis, cell adhesion and inflammation.
Gal-3 is a stable biomarker, under normal conditions, gal-3 is expressed in low levels, irrespective of age, sex and other factors, is highly expressed in activated macrophages, basophils and mast cells, can promote proliferation of myofibroblasts and collagen synthesis, leads to fibrosis of normal myocardial cells, further leads to heart failure, and is expressed in abnormal activity when lesions occur in vivo. At present, the research proves that the serum concentration of Gal-3 is obviously increased in diseases such as atrial fibrillation, myocardial fibrosis, acute coronary syndrome, heart failure and the like. Gal-3 is thus a potential new biomarker candidate for diagnosis, analysis and prognosis of various heart diseases, and can be developed as a combined indicator for assessing risk stratification, prognosis, etc. of patients suffering from acute and chronic heart failure.
The core raw material of the Galectin-3 immunodiagnostic reagent with excellent development performance is an anti-Galectin-3 monoclonal antibody, and the specificity and the sensitivity of some manufacturers are not high, so that the development of the Galectin-3 immunodiagnostic reagent with excellent development performance is very necessary, has great clinical significance for early screening, clinical diagnosis and prognosis evaluation of heart failure, and is expected to further promote localization of the diagnostic reagent.
Disclosure of Invention
In order to solve the problems of sensitivity and specificity, the invention provides a monoclonal antibody composition for resisting Galectin-3 protein. The antibody has excellent performance and high accuracy. Meanwhile, a chemiluminescent kit based on the Galectin-3 antibody is provided.
The invention provides the following technical scheme:
a monoclonal antibody composition for resisting Galectin-3 protein comprises Galectin-3-Clone1 and Galectin-3-Clone2,
heavy chain variable region amino acid sequence of Galectin-3-Clone 1:
EVQLQVSGKEGVKPGASVKMSCKASGFTFTLYVIHWVKQKPGQGLEWIGYKNPDIDGTKYNEKFKGKATLTSDKSSSTAFMELSSLTSEDSAVYYCARSGYGNYGLAWLAYWGQGTLVTVSS
light chain variable region amino acid sequence of Galectin-3-Clone 1:
QAVIQESALTTSPGETVTLTCRSSTVGVTTSNYANWVQEKPDHLFTGLIGGSPKTRAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCGWLYSNNWVFTKLTVK
heavy chain variable region amino acid sequence of Galectin-3-Clone 2:
EVQLQQKGPELVKPGASVEMSCKASGNFTSYVMHWVKQKPGQGLGWIGYINPYNYDTKYNSFKGKASLTSDKASSTAYMELSSLTSEDSAVSYCSVGGDFDYWGQGTKLTVSA
light chain variable region amino acid sequence of Galectin-3-Clone 2:
DVQMNQSPKMMSTEIKDIVSITCKASQDVSTAVAWKQSKPGQSQKLLIYWAATRHTGVPDRFTGSGSGTDFTLTISSVQAEDLALYYCQQHYTEPWTFGGGTKIKR
the preparation method of the monoclonal antibody of the Galectin-3 protein comprises the following steps:
expression production of Galectin-3 protein: searching an amino acid sequence of Galectin-3 protein on NCBI functional network, adding a histidine tag at the N end of protein amino acid, optimizing codons in an escherichia coli expression system by utilizing codon optimization software, cloning genes into a pET30a expression vector by utilizing NdeI & XhoI restriction enzyme cleavage sites after gene synthesis, constructing a pET30a-Galectin-3 expression plasmid, and sequencing and verifying the gene sequence.
Transforming pET30a-Galectin-3 expression plasmid into competent cells of escherichia coli BL21 (DE 3), picking single colony for induction expression, culturing in LB culture medium containing 50ug/ml kanamycin, culturing at 20-25 ℃ and 220rpm until OD600nm to 0.6-0.8, adding 0.2 mM IPTG for induction expression, inducing for 15-18 hours, rotating at 8000g, centrifuging for 10min, and collecting thalli.
Affinity purification of Galectin-3 protein: after the cell supernatant was sufficiently resuspended with salt and imidazole and filtered, affinity purification was performed with a preloaded gravity column, eluting and washing by gradient imidazole concentration, protein purity was checked by SDS-PAGE running, protein was dialyzed into phosphate buffer, sterile filtration was performed on a 0.22 μm filter, and protein concentration was determined by BCA.
Mixing and emulsifying Galectin-3 protein and Freund's adjuvant in equal volume after affinity purification, performing immunity measurement to 100 ug/mouse, performing booster immunization after 3 weeks, performing immunity measurement to 50 ug/mouse, collecting mouse blood to separate serum every 2 weeks later, measuring antibody titer by enzyme-linked immunosorbent assay, screening immunized mice to perform hybridoma fusion experiment, screening and culturing by HAT screening culture medium, taking Galectin-3 protein as an ELISA plate coating antigen, taking supernatant to perform enzyme-linked immunosorbent assay, screening out high-quality positive cell strains, performing two rounds of cell subcloning, cloning monoclonal cell strains, culturing and fermenting cell strains by serum-free, and collecting culture supernatant.
Application of a monoclonal antibody composition of anti-Galectin-3 protein in preparing an immunodiagnosis reagent for early screening of heart failure.
The monoclonal antibody composition is used in Galectin-3 chemiluminescence kit. The kit uses Galectin-3-Clone1 and Galectin-3-Clone2 as coating and detection antibodies, respectively.
Compared with the prior art, the invention has the beneficial effects that:
the invention provides an anti-Galectin-3 protein which is used for preparing a monoclonal antibody for diagnosis, the monoclonal antibody composition of the anti-Galectin-3 protein comprises Galectin-3-Clone1 and Galectin-3-Clone2, and can identify immunogens, and the antibody combination has the characteristics of specificity and high affinity.
Drawings
FIG. 1 is a graph showing the correlation between the detection kit of the present invention and the similar products.
Description of the embodiments
The technical solutions of the embodiments of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention, and it is apparent that the described embodiments are only some embodiments of the present invention, not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
Example 1 construction of Galectin-3 protein expression vector
Searching human Galectin-3 amino acid sequence on NCBI functional network, adding histidine tag at N end of protein amino acid, optimizing codon in mammal cell expression system by utilizing codon optimizing software, cloning gene into pET30a expression vector by utilizing NdeI & XhoI restriction enzyme cutting site after gene synthesis, constructing pET30a-Galectin-3 expression plasmid, and sequencing to verify gene sequence.
Example 2 expression production of Galectin-3 protein
Respectively transforming pET30a-Galectin-3 expression plasmids into competent cells of escherichia coli BL21 (DE 3), picking single colonies for induction expression, culturing in LB culture medium containing 50ug/ml kanamycin, culturing at 20-25 ℃ and 220rpm until OD600nm to 0.6-0.8, adding 0.2 mM IPTG for induction expression, inducing for 15-18 hours, rotating at 6000-8000g, centrifuging for 10min, and collecting thalli.
Example 3 affinity purification of Galectin-3 protein
The cells were resuspended in 20mM PB,300mM NaCl,10% glycerol, pH8.0 buffer, homogenized at high pressure of 800bar, spun at 10000-12000g, centrifuged for 30min, the supernatant was affinity purified with Ni Smart-6FF beads, 20mM PB,300mM NaCl,10% glycerol, 50mM imidazole, pH8.0 solution, 20mM PB,300mM NaCl,10% glycerol, 250mM imidazole, pH8.0 solution, eluted, SDS-PAGE running was performed to detect protein purity, protein was dialyzed to 20mM PB,300mM NaCl,10% glycerol, pH8.0 buffer, and after sterile filtration with 0.22 μm filter, BCA was assayed for protein concentration.
EXAMPLE 4 preparation of monoclonal antibodies
Mixing and emulsifying Galectin-3 protein and Freund's adjuvant in equal volume, performing subcutaneous multipoint injection with 100 ug/mouse for 3 weeks, performing boosting immunization, performing 50 ug/mouse for 2 weeks later, collecting mouse blood to separate serum each time, measuring antibody titer by enzyme-linked immunosorbent assay, screening the better immunized mouse for hybridoma fusion experiment, screening and culturing by about 10 days HAT screening culture medium, using Galectin-3 protein as enzyme-labeled plate coating antigen, taking supernatant for enzyme-linked immunosorbent assay, screening out high-quality positive cell strains, performing two rounds of cell subcloning, cloning monoclonal cell strains, culturing and fermenting cell strains by serum-free culture, collecting culture supernatant, performing antibody purification, and performing diagnostic performance analysis on the purified antibody.
EXAMPLE 5 monoclonal antibody Performance analysis
The kit is prepared based on the principle of a double antibody sandwich method and an acridine ester luminescence method.
1. Carboxyl magnetic bead coated antibody
Fully and uniformly mixing purchased carboxyl magnetic beads, taking out a corresponding amount of magnetic beads, placing the magnetic beads into a centrifuge tube, removing supernatant by using a magnetic rack, cleaning, adding coating activating solution, uniformly mixing, adding EDC dissolved by the coating activating solution, fully and uniformly mixing, and performing reverse activation for 0.5-1h at room temperature;
ultrasonic dispersing magnetic beads, cleaning for three times by using coating activating solution, adding the coating antibody of the invention, fully mixing uniformly, and then reversing the reaction at room temperature for 1-2h;
dispersing magnetic beads by ultrasonic, adding a sealing agent, fully and uniformly mixing, and sealing for 1-2h at room temperature in a reverse way;
and (3) ultrasonically dispersing the magnetic beads, removing the supernatant by using a magnetic frame, cleaning for three times, and adding a magnetic bead preservation solution to dilute the magnetic beads to a concentration of 0.25mg/mL for later use.
The formula of the magnetic bead preservation solution is 50mM Tris, 0.2% Tween-20, 0.85% NaCl, 2% BSA and 0.2% Proclin-300.
2. Acridinium ester labeled antibody
NHS esterified acridinium ester (NSP-DMAE-NHS) was combined with the coated antibody of the present invention in a molecular molar ratio of 10:1 in 1 XPBS, and mixing and labeling for 1-2h;
transferring the marking liquid into a 14kD dialysis bag after the reaction is finished, performing rotary dialysis in 1 XPBS, and changing the liquid for 6 times, wherein each time is 1-2 hours;
and (3) taking out the marking liquid after dialysis overnight, testing the protein content in the marking liquid by using a spectrophotometer, calculating and adding a protective liquid, fully and uniformly mixing, and then placing the mixture at 18-20 ℃ for preservation, and diluting the protein concentration to 0.5ug/mL for standby by using the marking preservation liquid during on-machine testing.
The formulation of the label stock solution is 0.1M MES buffer solution, 0.2% Tween-20, 0.85% NaCl, 2% BSA and 0.2% Proclin-300.
3. Preparing calibration product and quality control product
The Galectin-3 antigen was diluted to 0, 20, 100, 200, 1000, 2000, 10000pg/mL with antigen diluent, and dispensed into calibrator tubes.
And (3) respectively releasing Galectin-3 antigen to 100pg/mL and 1000 pg/mL by using antigen diluent, and subpackaging into quality control product tubes.
The antigen diluent is 1 XPBS and 1% bovine serum albumin.
The detection kit is compared with the similar products:
the Galectin-3 chemiluminescent detection kit in the example and the product of Roche corporation are subjected to correlation comparison on 120 clinical specimens, and the data are shown in FIG. 1. Correlation coefficient R 2 0.9939. The kit disclosed by the invention can accurately detect the Galectin-3 content, provides a basis for clinical diagnosis, and can fully meet the clinical in-vitro diagnosis detection requirement.
Detection kit sensitivity and precision investigation:
the blank and detection limits of the kit of the invention were studied according to the clinical and laboratory standards institute sensitivity verification analysis guideline file CLSI: EP17-A2, and the results showed that the blank and detection limits were 10 pg/mL and 20 pg/mL, respectively.
According to the precision verification analysis guideline file CLSI of the clinical and laboratory standards institute, EP5-A3 carries out precision research on the kit, 3 batches of reagents and calibrators are used for detecting 2 levels of quality control products, each time of detection is carried out twice a day in the morning and afternoon, continuous investigation is carried out for 5 days, and the result shows that the total indoor precision of each batch is less than 5%.
And (3) analyzing the anti-interference capability of the detection kit:
different concentrations of interferents were added to two serum samples at concentrations of Galectin-3 of approximately 100pg/mL and 1000 pg/mL, and the maximum concentration levels (no more than the highest clinically visible concentration) of the different interferents were studied using the non-added group as a control, with a relative deviation of less than 5% between the added group and the control group as an interference acceptable standard.
Table 1 assay data for anti-tamper capability of test kits
The results show that the concentration in table 1 does not significantly interfere with the detection results.
Finally, it should be noted that: the foregoing description is only a preferred embodiment of the present invention, and the present invention is not limited thereto, but it is to be understood that modifications and equivalents of some of the technical features described in the foregoing embodiments may be made by those skilled in the art, although the present invention has been described in detail with reference to the foregoing embodiments. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims (5)

1. A monoclonal antibody composition against Galectin-3 protein, characterized in that: comprises Galectin-3-Clone1 and Galectin-3-Clone2,
the amino acid sequence of the heavy chain variable region of the Galectin-3-Clone1 is shown as SEQ ID NO.1, and the amino acid sequence of the light chain variable region of the Galectin-3-Clone1 is shown as SEQ ID NO. 2;
the amino acid sequence of the heavy chain variable region of the Galectin-3-Clone2 is shown as SEQ ID NO.3, and the amino acid sequence of the light chain variable region of the Galectin-3-Clone2 is shown as SEQ ID NO. 4.
2. Use of the anti-Galectin-3 protein monoclonal antibody composition according to claim 1 in the preparation of an early screening immunodiagnostic reagent for heart failure.
3. Use of the anti-Galectin-3 protein monoclonal antibody composition according to claim 2 for preparing an early screening immunodiagnostic reagent for heart failure, characterized in that: the monoclonal antibody composition is used in Galectin-3 chemiluminescence kit.
4. Galectin-3 chemiluminescence kit is characterized in that: a Galectin-3-Clone1 and a Galectin-3-Clone2 according to claim 1.
5. The Galectin-3 chemiluminescent kit of claim 4 wherein: the kit uses Galectin-3-Clone2 and Galectin-3-Clone1 as a coating antibody and a detection antibody respectively.
CN202311420944.XA 2023-10-30 2023-10-30 Monoclonal antibody composition for resisting Galectin-3 protein and application thereof Active CN117143242B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311420944.XA CN117143242B (en) 2023-10-30 2023-10-30 Monoclonal antibody composition for resisting Galectin-3 protein and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202311420944.XA CN117143242B (en) 2023-10-30 2023-10-30 Monoclonal antibody composition for resisting Galectin-3 protein and application thereof

Publications (2)

Publication Number Publication Date
CN117143242A true CN117143242A (en) 2023-12-01
CN117143242B CN117143242B (en) 2024-03-29

Family

ID=88903047

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202311420944.XA Active CN117143242B (en) 2023-10-30 2023-10-30 Monoclonal antibody composition for resisting Galectin-3 protein and application thereof

Country Status (1)

Country Link
CN (1) CN117143242B (en)

Citations (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101730523A (en) * 2007-07-10 2010-06-09 伊莱利利公司 Glp-1-fc fusion protein formulation
CN103906528A (en) * 2011-06-24 2014-07-02 安米林药品有限责任公司 Methods of treating diabetes with sustained release formulations of GLP-1 receptor agonists
CN104293834A (en) * 2014-10-11 2015-01-21 上海兴迪金生物技术有限公司 Preparation method of GLP (Glucagon-Like Peptide) -1 or analogue thereof and antibody Fc fragment fusion protein
CN104327187A (en) * 2014-10-11 2015-02-04 上海兴迪金生物技术有限公司 Recombinant human GLP-1-Fc fusion protein
CN105367664A (en) * 2015-11-04 2016-03-02 成都贝爱特生物科技有限公司 Preparation method for dual-functional fusion protein capable of activating GLP-1 receptor and Amylin receptor and application of fusion protein
CN107698684A (en) * 2016-08-03 2018-02-16 广东东阳光药业有限公司 The fusion proteins of GLP 1 of Fc portion of immunoglobulin comprising mutation
CN108103088A (en) * 2017-12-21 2018-06-01 广东东阳光药业有限公司 Recombinate optimization gene and its application of GLP-1 analog Fc fusion proteins
CN108350054A (en) * 2015-10-28 2018-07-31 株式会社柳韩洋行 Bifunctional protein and pharmaceutical composition comprising it
CN108424460A (en) * 2017-02-13 2018-08-21 成都贝爱特生物科技有限公司 The fusion protein of GLP-1 analogs and davalintide analogs preparation and application thereof
CN108570109A (en) * 2017-03-14 2018-09-25 广东东阳光药业有限公司 Include double target spot fusion proteins of Fc portion of immunoglobulin
CN108623691A (en) * 2017-03-17 2018-10-09 北京比洋生物技术有限公司 IgG sample long lasting immune fusion proteins and its application
CN110121355A (en) * 2016-11-10 2019-08-13 株式会社柳韩洋行 For preventing or treating the pharmaceutical composition comprising fusion protein of hepatitis, liver fibrosis and cirrhosis
CN110139664A (en) * 2016-12-22 2019-08-16 艾瑞克有限公司 Glucagon-like-peptide-1 (GLP-1) receptor stimulating agent composition
CN110248958A (en) * 2017-08-20 2019-09-17 夸德卢普生物公司 Polymer, the tetramer and eight aggressiveness
CN110526982A (en) * 2018-05-23 2019-12-03 信立泰(成都)生物技术有限公司 A kind of purification process of human glucagon-like-peptide-1 analog fusion
CN110545838A (en) * 2017-03-08 2019-12-06 因塔西亚制药公司 apparatus and method for administering nausea-causing compounds from a drug delivery device
WO2020005003A1 (en) * 2018-06-29 2020-01-02 주식회사 와이바이오로직스 Monoclonal antibody specifically binding to lag-3 and use thereof
CN110650747A (en) * 2017-06-01 2020-01-03 伊莱利利公司 Dolaglutide for treating chronic kidney disease
CN110709520A (en) * 2017-04-21 2020-01-17 株式会社柳韩洋行 Method for producing bifunctional proteins and derivatives thereof
CN110878127A (en) * 2018-09-06 2020-03-13 浙江柏拉阿图医药科技有限公司 Long-acting recombinant GLP1-Fc-CD47 protein and preparation and application thereof
CN111108117A (en) * 2017-09-22 2020-05-05 瑞泽恩制药公司 Glucagon-like peptide 1 receptor agonists and uses thereof
JP2021162342A (en) * 2020-03-30 2021-10-11 アークレイ株式会社 Analysis of human galectin-3, detection, antibody relating to measurement, method and kit
CN113817064A (en) * 2021-11-22 2021-12-21 南京佰抗生物科技有限公司 Anti-human CHI3L1 mouse-derived monoclonal antibody and application thereof
CN116183931A (en) * 2022-12-30 2023-05-30 武汉明德生物科技股份有限公司 Galectin-3 magnetic particle chemiluminescence immune quantitative detection kit
CN116715760A (en) * 2023-07-31 2023-09-08 南京佰抗生物科技有限公司 Monoclonal antibody of anti-influenza B virus nucleocapsid protein and application thereof
CN116874597A (en) * 2023-09-06 2023-10-13 南京佰抗生物科技有限公司 Monoclonal antibody of mouse anti-human vascular endothelial growth factor, preparation method and application thereof

Patent Citations (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101730523A (en) * 2007-07-10 2010-06-09 伊莱利利公司 Glp-1-fc fusion protein formulation
CN103906528A (en) * 2011-06-24 2014-07-02 安米林药品有限责任公司 Methods of treating diabetes with sustained release formulations of GLP-1 receptor agonists
CN104327187A (en) * 2014-10-11 2015-02-04 上海兴迪金生物技术有限公司 Recombinant human GLP-1-Fc fusion protein
CN104293834A (en) * 2014-10-11 2015-01-21 上海兴迪金生物技术有限公司 Preparation method of GLP (Glucagon-Like Peptide) -1 or analogue thereof and antibody Fc fragment fusion protein
CN108350054A (en) * 2015-10-28 2018-07-31 株式会社柳韩洋行 Bifunctional protein and pharmaceutical composition comprising it
CN105367664A (en) * 2015-11-04 2016-03-02 成都贝爱特生物科技有限公司 Preparation method for dual-functional fusion protein capable of activating GLP-1 receptor and Amylin receptor and application of fusion protein
CN107698684A (en) * 2016-08-03 2018-02-16 广东东阳光药业有限公司 The fusion proteins of GLP 1 of Fc portion of immunoglobulin comprising mutation
CN110121355A (en) * 2016-11-10 2019-08-13 株式会社柳韩洋行 For preventing or treating the pharmaceutical composition comprising fusion protein of hepatitis, liver fibrosis and cirrhosis
CN110139664A (en) * 2016-12-22 2019-08-16 艾瑞克有限公司 Glucagon-like-peptide-1 (GLP-1) receptor stimulating agent composition
CN108424460A (en) * 2017-02-13 2018-08-21 成都贝爱特生物科技有限公司 The fusion protein of GLP-1 analogs and davalintide analogs preparation and application thereof
CN110545838A (en) * 2017-03-08 2019-12-06 因塔西亚制药公司 apparatus and method for administering nausea-causing compounds from a drug delivery device
CN108570109A (en) * 2017-03-14 2018-09-25 广东东阳光药业有限公司 Include double target spot fusion proteins of Fc portion of immunoglobulin
CN108623691A (en) * 2017-03-17 2018-10-09 北京比洋生物技术有限公司 IgG sample long lasting immune fusion proteins and its application
CN110709520A (en) * 2017-04-21 2020-01-17 株式会社柳韩洋行 Method for producing bifunctional proteins and derivatives thereof
CN110650747A (en) * 2017-06-01 2020-01-03 伊莱利利公司 Dolaglutide for treating chronic kidney disease
CN110248958A (en) * 2017-08-20 2019-09-17 夸德卢普生物公司 Polymer, the tetramer and eight aggressiveness
CN111108117A (en) * 2017-09-22 2020-05-05 瑞泽恩制药公司 Glucagon-like peptide 1 receptor agonists and uses thereof
CN108103088A (en) * 2017-12-21 2018-06-01 广东东阳光药业有限公司 Recombinate optimization gene and its application of GLP-1 analog Fc fusion proteins
CN110526982A (en) * 2018-05-23 2019-12-03 信立泰(成都)生物技术有限公司 A kind of purification process of human glucagon-like-peptide-1 analog fusion
WO2020005003A1 (en) * 2018-06-29 2020-01-02 주식회사 와이바이오로직스 Monoclonal antibody specifically binding to lag-3 and use thereof
CN110878127A (en) * 2018-09-06 2020-03-13 浙江柏拉阿图医药科技有限公司 Long-acting recombinant GLP1-Fc-CD47 protein and preparation and application thereof
JP2021162342A (en) * 2020-03-30 2021-10-11 アークレイ株式会社 Analysis of human galectin-3, detection, antibody relating to measurement, method and kit
CN113817064A (en) * 2021-11-22 2021-12-21 南京佰抗生物科技有限公司 Anti-human CHI3L1 mouse-derived monoclonal antibody and application thereof
CN116183931A (en) * 2022-12-30 2023-05-30 武汉明德生物科技股份有限公司 Galectin-3 magnetic particle chemiluminescence immune quantitative detection kit
CN116715760A (en) * 2023-07-31 2023-09-08 南京佰抗生物科技有限公司 Monoclonal antibody of anti-influenza B virus nucleocapsid protein and application thereof
CN116874597A (en) * 2023-09-06 2023-10-13 南京佰抗生物科技有限公司 Monoclonal antibody of mouse anti-human vascular endothelial growth factor, preparation method and application thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NATALIYA HRYNCHYSHYN等: "Galectin-3: A new biomarker for the diagnosis, analysis and prognosis of acute and chronic heart failure", ARCHIVES OF CARDIOVASCULAR DISEASES, vol. 106, no. 10, 31 October 2013 (2013-10-31), pages 541 - 546, XP028742322, DOI: 10.1016/j.acvd.2013.06.054 *
胡欣;王军奎;: "半乳糖凝集素3与心力衰竭的关系", 中华老年心脑血管病杂志, no. 01, 4 January 2017 (2017-01-04), pages 89 - 91 *

Also Published As

Publication number Publication date
CN117143242B (en) 2024-03-29

Similar Documents

Publication Publication Date Title
JP3544544B2 (en) Use of human neutrophil lipocalin (HNL) as a diagnostic marker and anti-HNL-antibody preparation
CN109975536B (en) Anti-mullerian hormone latex enhanced turbidimetry detection kit and preparation and use methods thereof
CN109580959B (en) ELISA kit for detecting heparin-binding epidermal growth factor
SG176509A1 (en) Methods for producing soluble multi-membrane-spanning proteins
EP2515114B1 (en) Method for diagnosing malignant tumor
CN116874597B (en) Monoclonal antibody of mouse anti-human vascular endothelial growth factor and application
KR20190088510A (en) Antibody assay
CN117003878B (en) Monoclonal antibody for resisting sFLT-1 protein and application thereof
CN114478785A (en) Mouse-derived monoclonal antibody of anti-human CHI3L1 and application
CN117143242B (en) Monoclonal antibody composition for resisting Galectin-3 protein and application thereof
CN116874596B (en) Monoclonal antibody of anti S100 beta protein, preparation method and application thereof
CN112094355B (en) Composite quality control product for clinical diagnosis and preparation method thereof
US9347950B2 (en) Moesin fragments associated with immune thrombocytopenia
JP2000512123A (en) Nephropathy-related immunoglobulin G and antibodies therefor
CN115951068A (en) Kit for detecting TGF-beta 1, detection method and application
CN117285635B (en) Monoclonal antibody composition for resisting heparin binding protein and application thereof
CN117003869B (en) anti-IL-10 protein monoclonal antibody composition and application
CN117285625B (en) Anti-prolactin monoclonal antibody and application thereof
CN117430701A (en) Monoclonal antibody composition of anti-human calprotectin and application
JP4424775B2 (en) Method for detecting antigenic protein
CN111269310B (en) C-P tandem expression recombinant protein and gene thereof, preparation method, application and C peptide detection kit
WO2023061388A1 (en) Immunoassay of galectin-3
EP4063845A1 (en) Method for detecting cancer bone metastasis and detection reagent
CN114609394A (en) Anti-mullerian tube hormone detection kit, monoclonal antibody and hybridoma cell strain
JPS62215599A (en) Glycitol lysine derivative

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant